Imprimis Pharma (IMMY) Reports Q1 Revenues Above Estimates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Imprimis Pharmaceuticals Announces First Quarter 2018 Results
May 15, 2018 4:01 PM EDTSAN DIEGO, May 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported financial results for the first quarter 2018.
Notable Highlights:
Revenue of $8.9 million, up 45% year-over-year Gross ophthalmology-related revenue of $7.0 million, up 91% year-over-year Gross Margin of 54%, compared to 45% in Q1 2017 Adjusted... More